Skip to main content
TipRanks
Go Ultimate75% OFF

Zimmer Biomet Holdings (0QQD) AI Stock Analysis

1 Followers
GB:0QQD

Zimmer Biomet Holdings

(LSE:0QQD)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Revenue Growth and Portfolio BreadthZimmer Biomet combines a multi-year upward revenue trajectory with broad momentum across hips, S.E.T., technology and data. This diversification reduces reliance on one product line, supports recurring procedure-driven demand, and gives the company multiple avenues to sustain growth over the next several quarters.
Negative Factors
Knee Franchise WeaknessThe knee franchise remains a meaningful area of weakness, with declines in both U.S. and international markets and management expecting continued near-term pressure. Persistent underperformance could dilute growth from stronger hip and technology categories and indicates unresolved commercial execution challenges.

Zimmer Biomet Holdings (0QQD) vs. iShares MSCI United Kingdom ETF (EWC)

-5%0%5%10%15%20%25%30%GB:0QQD0.00%EWC+18.88%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
CHF 19.19B
Dividend Yield
1.08%
Average Volume (3M)
―
Price to Earnings (P/E)
25.6
Beta (1Y)
0.04
Revenue Growth
0.21%
EPS Growth
-8.55%
Country
UK
Employees
17,000
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Zimmer Biomet Holdings Business Overview & Revenue Model

Company Description

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products...

Zimmer Biomet Holdings Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 11, 2027
Earnings Call SentimentPositive

The call was broadly positive. Zimmer Biomet reported solid third-quarter growth, strong performance across Hips, S.E.T. and technology, significant cash generation, progress in its commercial transformation and multiple increases to its 2026 outlook. The main challenges were declining knee sales, China-related headwinds, margin pressure from manufacturing costs and ongoing investment in the U.S. sales force. Management expressed confidence in the long-term strategy and expects improved knee performance and additional growth catalysts in 2027.

Positive Updates

Solid Third-Quarter Revenue Growth
Third-quarter total net sales were $2.63 billion, representing 3.1% reported growth and 3.7% constant currency growth versus the third quarter of 2025. Excluding the negative impact of the China distributor network consolidation strategy, constant currency growth would have been 4.7%.

Negative Updates

Knee Business Decline
Global Knee sales declined 2.6% on a constant currency basis, including a 2% decrease in the U.S. and a 3.4% decrease internationally. Management expects continued near-term pressure in the knee business.

Company Guidance

Zimmer Biomet raised its 2026 organic constant currency sales growth guidance to a range of 3% to 3.5% from 2.25% to 3.25%, adjusted earnings per share guidance to $8.50 to $8.60 from $8.47 to $8.59, and reported sales growth guidance to 4.4% to 4.9% from 3.9% to 4.9%; foreign exchange is expected to be an approximate 25 basis point tailwind, Paragon 28 to contribute 110 basis points, China-related headwinds to total nearly 100 basis points in the fourth quarter and roughly 50 basis points for the full year 2026, adjusted gross margin to be around 72%, adjusted operating margin to decline a little more than 50 basis points year-over-year, net interest and other nonoperating expenses to be $300 million, the adjusted tax rate approximately 18%, share repurchases approximately $1 billion, fully diluted weighted average shares around 193 million, and free cash flow to grow 9% to 11%; pricing is expected to be flat to 100 basis points of pressure, the company aspires to a 6% WAMGR by the end of the decade, expects 2027 to be a better year compared to 2026, and anticipates Monogram can launch in the first half of 2027, pending approval.

Zimmer Biomet Holdings Risk Analysis

Zimmer Biomet Holdings disclosed 32 risk factors in its most recent earnings report. Zimmer Biomet Holdings reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Zimmer Biomet Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0QQD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MDTMDT81Outperform$131.60B25.2710.60%2.78%9.77%12.28%
SYKSYK75Outperform$118.29B32.7415.61%1.13%7.87%22.82%
GMEDGMED73Outperform$9.34B17.0311.82%―13.35%32.22%
SNNSNN69Neutral$12.96B20.4012.25%2.56%5.26%31.02%
BVSBVS66Neutral$881.37M12.3527.23%―3.87%623.68%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

0%50%100%GB:0QQDMDTSNNSYKGMEDBVSDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0QQD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0QQDZimmer Biomet Holdings77.380.000.00%
MDTMedtronic102.885.315.45%
SNNSmith & Nephew Snats30.97-0.74-2.33%
SYKStryker Corp310.72-44.86-12.62%
GMEDGlobus Medical70.50-12.92-15.49%
BVSBioventus, Inc.10.463.4749.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.